Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 8778940
Chemical inducers of neurogenesis
granted -
US 8778913
Antimicrobial compositions for treating microbial infections
granted -
US 8778897
Method of treatment using Ξ±-1-adrenergic agonist compounds
granted -
US 8778608
CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
granted -
US 8778876
Small-molecule inhibitors of Dengue and West Nile virus proteases
granted -
US 8778343
Antibodies that bind tau oligomers
granted -
US 8771965
Methods and compositions involving nucleotide repeat disorders
granted -
US 8771731
Antimicrobial nanoemulsion compositions and methods
granted -
US 8772247
Anti-parasitic compounds
granted -
US 8771713
Method and process for the production of multi-coated recognitive and releasing systems
granted -
US 8765935
Nucleosides with antiviral and anticancer activity
granted -
US 8765797
TG2 inhibitors and uses thereof
granted -
US 8765673
Methods for promoting wound healing and/or reducing scar formation
granted -
US 8765671
Methods and compositions for modulation of blood-neural barrier
granted -
US 8765171
Methods and compositions for liposomal formulation of antigens and uses thereof
granted -
US 8765168
Compositions of a fluorapatite and methods of use
granted -
US 8764828
System and method for forming bone, ligament, and bone-ligament constructs
granted -
US 8765147
Endophytic fungi from Pteromischum sp. plant, compounds and methods of use
granted -
US 8768431
Systems and methods for tissue imaging
granted -
US 8758755
Stem cell fusion model of carcinogenesis
granted -
US 8759492
Engineered red-shifted channelrhodopsin variants
granted -
US 8759325
Compositions and methods of treatment for inflammatory diseases
granted -
US 8759327
Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
granted -
US 8759296
Bone morphogenic protein binding peptide
granted -
US 8759006
PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia
granted -
US 8758778
Polymeric nano-carriers with a linear dual response mechanism and uses thereof
granted -
US 8759301
Gene fusion targeted therapy
granted -
US 8758723
Compositions and methods for cellular imaging and therapy
granted -
US 8759340
Benzodiazepinone compounds useful in the treatment of skin conditions
granted -
US 8759392
Amides as inhibitors of human secreted phospholipase A2
granted -
US 8753302
Indwelling heat exchange catheter and method of using same
granted -
US 8754124
Oligo-benzamide compounds and their use in treating cancers
granted -
US 8754050
Macrocyclic compounds useful as inhibitors of histone deacetylases
granted -
US 8754034
Structure-based design of peptide inhibitors of amyloid fibrillation
granted -
US 8754051
Peptide modulators of the Ξ΄PKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof
granted -
US 8753660
Activating extraction of demineralized bone matrix
granted -
US 8748601
Selective serine/threonine kinase inhibitors
granted -
US 8748473
Methods of treating post-traumatic stress disorder using pro-neurogenic compounds
granted -
US 8748408
Methods of treatment of mitochondrial disorders
granted -
US 8747872
Nanoemulsion therapeutic compositions and methods of using the same
granted -
US 8747843
Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
granted -
US 8748176
Generation of choroid plexus epithelial cells from human embryonic stem cells
granted -
US 8748385
Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
granted -
US 8748591
Chimeric sindbis-western equine encephalitis virus and uses thereof
granted -
US 8748632
Positive allosteric modulators of group II mGluRs
granted -
US 8740872
Magnetically-targeted treatment for cardiac disorders
granted -
US 8742121
Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein
granted -
US 8741937
Gamma glutamyl transpeptidase inhibitors and methods of use
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory